Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults by Gostelow, Martyn et al.
Pharmacokinetics and safety of recently approved drugs used to
treat methicillin-resistant Staphylococcus aureus infections in
infants, children, and adults
Martyn Gostelow, BS1, Daniel Gonzalez, PharmD, PhD1,2, P. Brian Smith, MD, MPH, MHS1,3,
and Michael Cohen-Wolkowiez, MD, PhD1,3,*
1Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
2Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of
Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
Summary
Methicillin-resistant Staphylococcus aureus (MRSA) remains a significant cause of morbidity in
hospitalized infants. Over the past 15 years, several drugs have been approved for the treatment of
S. aureus infections in adults (linezolid, quinupristin/dalfopristin, daptomycin, telavancin,
tigecycline, and ceftaroline). The use of there majority of these drugs has extended into the
treatment of MRSA infections in infants, frequently with minimal safety or dosing information.
Only linezolid is approved for use in infants, and pharmacokinetic data in infants are limited to
linezolid and daptomycin. Pediatric trials are underway for ceftaroline, telavancin, and
daptomycin; however, none of these studies includes infants. Here, we review current
pharmacokinetic, safety, and efficacy data of these drugs with a specific focus in infants.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) infections are common and are
associated with increased mortality, morbidities, and healthcare costs [1,2]. In 2012, in the
United States, there were an estimated 80,461 cases of invasive MRSA infections [3]. A
retrospective analysis of 25 children's hospitals reported that the incidence of MRSA
infections increased 10-fold between 1999 and 2008 (2 cases vs. 21 cases per 1000,
P<0.001) [4]. Furthermore, the proportion of staphylococcal infections due to MRSA in
children's hospitals in the United States doubled in the same time period (15% vs. 36%) [4].
In 2010, invasive MRSA infection incidence was higher in infants <90 days of age
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compared with older infants and children— 4 times higher in this population than in infants
aged 3–11 months and more than 40 times higher than in children aged 11–17 years [5].
Given the increase in MRSA infections over the last decade, the percentage of hospitalized
children with S. aureus infection that received anti-MRSA antibiotics increased between
1999 and 2008 (52% vs. 79%), while the percentage of hospitalized children receiving beta-
lactam drugs decreased (66% vs. 30%, P<0.001) [4]. During this time period, the percentage
of hospitalized children with S. aureus infection given clindamycin and linezolid increased
(clindamycin, 21% vs. 63%; linezolid, 0% vs. 5%) while vancomycin use remained stable
(36% vs. 37%) [4].
Current treatment options for infants with MRSA infection based on the clinical practice
guidelines by the Infectious Diseases Society of America vary depending on the site of
infection [6]. First-line treatment is with intravenous (IV) vancomycin for severe
manifestations of MRSA infection [6]. Alternative antibiotic treatment includes
clindamycin, linezolid, daptomycin, quinupristin/dalfopristin, rifampin, telavancin, or
trimethoprimsulfamethoxazole [6].
The objective of this report is to review available pharmacokinetic (PK), safety, and efficacy
data of recently approved antibiotics for MRSA infection in infants. Our focus was to
describe data pertaining to the infant population, though all age groups are briefly discussed.
Clinical trials in infants are needed because the PK, efficacy, and safety of drugs may be
significantly different from that observed in adults. Maturation in drug elimination pathways
and differences in body composition affect drug disposition, often necessitating age- or
weight-based dosing recommendations [7]. In addition, exposure-response relationships are
also needed to characterize developmental factors that affect drug action. The disease
process of MRSA infection in infants can reasonably be assumed to be similar to adults, and
if the exposure-response relationship is reasonably assumed to be the same in infants and
adults, the Food and Drug Administration (FDA) only requires PK and safety studies for
drug labeling changes in the pediatric population.
Methods
We conducted searches for each drug using the PubMed database and the following medical
subject heading (MeSH) and title/abstract [tiab] terms: pharmacokinetics [MeSH],
pharmacokinetics [subheading], safety [tiab], efficacy [tiab], and the drug name [tiab]. We
also retrieved drug labels from the FDA registry [201]. We included all drugs approved in
the last 15 years for use against staphylococcal infections (linezolid, daptomycin,
quinupristindalfopristin, telavancin, tigecycline, and ceftaroline) (Table 1). There were no
exclusion criteria in our search strategy. All articles regarding PK, safety, and efficacy in
infants were included. Articles representative of PK, safety, and efficacy in children and
adults were included at the authors’ discretion.
Linezolid
Linezolid is a synthetic oxazolidinone that binds to the bacterial 50S ribosomal subunit
preventing the formation of the 70S initiation complex and stopping the initiation of
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translation [8,9,101]. Linezolid is primarily bacteriostatic against enterococci and
staphylococci isolates and bactericidal against the majority of streptococci isolates [101].
The drug is highly effective against gram-positive bacteria and has been found in vitro to
have 90% minimum inhibitory concentration values (MIC90) of 1, 2, and 4 μg/mL against
streptococci, enterococci, and staphylococci, respectively [10].
Pharmacokinetics of Linezolid
Linezolid is given either orally or as an IV infusion at a dose of 600 mg in adults [101].
Linezolid is extensively absorbed following oral dosing with a bioavailability of 100% [11].
Linezolid follows a linear PK elimination profile after either single or multiple dose
administration. In adults, the time at maximum concentration (Tmax) of the drug is 0.5 hours
following a 600 mg IV dose. The volume of distribution (Vd) of linezolid is 0.65 L/kg, and it
is 31% bound to plasma proteins [101]. The systemic clearance (CL) of linezolid is 8.3 L/h
[12,13,101]. Linezolid is primarily excreted renally; over 35% of the drug is excreted as the
parent drug in urine, and an additional 50% is excreted as metabolites in urine [14,15]. The
elimination half-life (T1/2) of the drug in adults is approximately 4.9 hours (Table 2)
[13,101].
The majority of the linezolid PK data in children comes from 4 trials evaluating 182 children
aged 0–18 years, of whom 41 were <3 months of age [101]. Linezolid was given as a 10
mg/kg IV infusion in subjects <11 years and as a 600 mg IV infusion in subjects aged 12–18
years [101]. The CL of linezolid varied significantly as a function of the postnatal age and
gestational age of the infant at birth. The mean CL in premature infants <1 week of age was
0.12 L/kg/h compared with 0.23 L/kg/h for term infants <1 week of age [16]. Following the
first week of life, linezolid body weight-normalized CL in infants increased to 0.31 L/kg/h,
approximately 3 times that of the adult estimate (0.1 L/kg/h). Linezolid weight-normalized
CL remained elevated for the first 3 months of life and reached adult values by adolescence
(Table 2) [16,101].
Safety and Efficacy of Linezolid
The safety and efficacy of linezolid in adults have been evaluated in a number of large
clinical trials. For adults treated with 400 mg of linezolid every 12 hours for skin and skin
structure infections (n=548), 25% suffered at least 1 drug-related adverse event [101]. The
most common of these reactions were diarrhea (5%), nausea (3%), and headache (3%).
These events were comparable to the comparator, clarithromycin, with which subjects also
reported diarrhea (5%), nausea (3%), and headache (2%). The discontinuation rate for
linezolid due to drug-related adverse events was also similar to clarithromycin (3.5% vs.
2.4%, respectively) [101].
A separate study in adults (n=66) compared the efficacy of linezolid versus vancomycin for
the treatment of MRSA skin and skin structure infection. Subjects were either given
linezolid 600 mg every 12 hours or vancomycin 1 g every 12 hours. Clinical efficacy as
measured by cure rate in microbiologically evaluable subjects was higher in subjects treated
with linezolid than in subjects treated with vancomycin (79% vs. 73%) [101].
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The safety and efficacy of linezolid in pediatric subjects has been evaluated in 2 phase 3
comparator-controlled clinical trials [17,18,101]. The first study examined the safety and
efficacy of linezolid versus vancomycin for the treatment of known or suspected antibiotic-
resistant, gram-positive infection [18]. In the first study (n=321, ages 0–11 years), 219
subjects (median age 1.5 years) were given IV linezolid (10 mg/kg every 8 hours), while 102
subjects (median age 1.8 years) received IV vancomycin (10–15 mg/kg every 8 hours) [18].
Drug-related adverse events were more frequent in the vancomycin-treated group than in the
linezolid-treated group (34% vs. 19%, P=0.003) [18]. Discontinuation due to drug-related
adverse events was also higher in the vancomycin- treated group (6% vs. 1%, P=0.008) [18].
The most common adverse event seen in linezolid-treated subjects was diarrhea (4%).
Efficacy of linezolid as measured by overall cure rate in clinically evaluable subjects was
similar to vancomycin-treated subjects (89% vs. 84%, P=0.31) [18].
The second study (n=508) examined the safety and efficacy of linezolid for the treatment of
skin and skin structure infections in children [17]. Dosing of subjects in the trial varied
based on age. Linezolid was given as an oral suspension to 146 subjects aged 5–11 years (10
mg/kg every 12 hours) and 102 subjects aged 12–17 years (600 mg every 12 hours).
Adverse events occurring in >5% of linezolid-treated subjects included diarrhea (8%) and
headache (6%), which were similar to the rates seen in children receiving the comparator,
cefadroxil (8% and 4%, respectively). A trend towards lower discontinuation due to adverse
events was observed for the linezolid-treated group (2% vs. 4%), but this difference was not
found to be statistically significant [17]. One serious drug-related adverse event was
reported in a subject treated with linezolid who had a highly elevated lipase level that
returned to normal after 3 days [17].
The safety of linezolid in infants was evaluated in a phase 3 study (n=63), which examined
the safety and efficacy of linezolid versus vancomycin for the treatment of known or
suspected antibiotic-resistant, gram-positive infection [19]. Forty-three children and 20
infants were either given IV linezolid 10 mg/kg every 8 hours or IV vancomycin 10–15
mg/kg every 6–24 hours. Drug-related adverse events occurred more frequently in subjects
treated with vancomycin than in those treated with linezolid (32% vs. 12%, P=0.06).
Adverse events that occurred more commonly in subjects treated with linezolid included:
thrombocytopenia (5%), candidiasis (2%), hyperglycemia (2%), and anemia (2%). The
efficacy of linezolid in clinically evaluable subjects successfully treated for bacteremia was
similar to those treated with vancomycin (84% vs. 77%, P=0.55) [19].
Daptomycin
Daptomycin is the first drug in the lipopeptide class of antimicrobials. It is derived from a
fermentation product of Streptomyces roseosporus [102]. Daptomycin forms channels
through which K+ moves out of the cell, causing a change in the membrane potential [20].
The change in membrane potential results in inhibition of DNA, RNA, and protein synthesis
in the bacterium [102]. This mechanism of action allows the drug to have bactericidal
activity against multiple strains of gram-positive, antibiotic-resistant bacterium [21].
Daptomycin has been found in vitro to have an MIC90 of 0.5 μg/mL, 0.5 μg/mL, and 2–4
μg/mL against staphylococci, streptococci, and enterococci, respectively [21,22].
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Daptomycin is given in adults as an IV infusion at a dose of 4 mg/kg every 24 hours [102].
In healthy adults, daptomycin has linear PK following single or multiple doses up to 8
mg/kg. Daptomycin distributes primarily into extracellular fluid (Vd of 0.1 L/kg) and is 87–
93% reversibly bound to plasma proteins [23,102]. The CL of the drug in healthy adults is
0.011 L/kg/h [102]. Daptomycin is renally excreted, and dosing must be adjusted for adult
subjects who have impaired creatinine clearance or who are undergoing dialysis [24].
Daptomycin has a T1/2 of 8–9 hours (Table 2) [20,24–27].
At doses of 4 mg/kg every 24 hours in children 12–17 years of age, the area under the
concentration curve (AUC) of daptomycin approximated adult values shown to be
therapeutically effective (375 μg/mL*h vs. 414–494 μg/mL*h, respectively) [26–28,102].
However, for children aged 2–12 years who were given 4 mg/kg every 24 hours, the
exposure to daptomycin (AUC) was lower than in adults (215–271 μg/mL*h vs. 414–494
μg/mL*h, respectively) [26–28,102]. Larger weight-based doses or more frequent dosing of
daptomycin is required in children <12 years of age to match adult AUC values [28].
In a study of a single 6 mg/kg dose of daptomycin in 20 infants (median gestational age 32
weeks; range 23–40 weeks), the median exposure from 0–24 hours (AUC0-24) of the drug in
infants was significantly lower than that reached in adults (262 μg/mL*h vs. 414–494 μg/
mL*h) [26,27,29]. This was due to the increased body weight-normalized CL of the drug in
infants (0.02 L/kg/h) compared with adults (0.01 L/kg/h) [25,29]. The investigators
concluded that higher doses of daptomycin were needed for treatment of infection in infants
[29]. A case series examined the PK of daptomycin given at higher daily doses (6 mg/kg
every 12 hours) in 2 infants (gestational age 23 weeks and 32 weeks) at postnatal ages of 31
weeks and 35 weeks, respectively [30]. This increased dosing regimen of 6 mg/kg every 12
hours led to peak and trough values (Cmax, Cmin) of the drug in infant 1 (41.7mg/L,
12.7mg/L) and infant 2 (36.7mg/L, 16.3mg/L) that closely approximated the clinically
effective levels in adults (58mg/L, 7mg/L) treated with daptomycin (4 mg every 24 hours)
(Table 2) [30].
Safety and Efficacy of Daptomycin
A phase 3 study in adults (n=558) compared daptomycin against comparator treatment (IV
cloxacillin, nafcillin, oxacillin, flucloxacillin 4–12 g every 12 hours or vancomycin 1 g
every 12 hours) for complicated skin and skin structure infection. Eighteen percent of adults
given daptomycin 4 mg/kg daily suffered at least 1 drug-related adverse event [31]. Adverse
events reported in >5% of subjects included: constipation (6%), nausea (6%), injection site
reaction (6%), headache (5%), and diarrhea (5%). Severe adverse events were observed in
11% of subjects given daptomycin vs. 9% of subjects given comparator medications [31].
The only severe adverse event to occur more often in daptomycin-treated subjects than in
comparator-treated subjects was cellulitis (1% vs. 0%). For the treatment of complicated
skin and skin structure infections, the clinical success rate of daptomycin was similar to the
clinical success rate seen for other comparator antimicrobials (83% vs. 84%, respectively)
[31].
Gostelow et al. Page 5






















In another phase 3 study (n=120), daptomycin (6 mg/kg every 24 hours) was evaluated
versus comparator medications (IV nafcillin, oxacillin or flucloxacillin 2 g every 4 hours or
vancomycin 1 g every 12 hours) for the treatment of bacteremia and endocarditis in adults
[32]. Thirty-five percent of subjects suffered at least 1 drug-related adverse event, of which
8% were severe enough to warrant daptomycin treatment discontinuation. Adverse events
observed in >5% of daptomycin-treated subjects included: anemia, diarrhea, vomiting
constipation, nausea, hypokalemia, renal impairment, headache, and peripheral edema.
Creatinine kinase (CK) levels were elevated in 25% of subjects treated with daptomycin,
and 2.5% of subjects discontinued treatment due to elevated CK levels. For the treatment of
bacteremia and endocarditis, the clinical success rate of daptomycin was comparable to
standard therapy with gentamicin and an anti-staphylococcal penicillin or vancomycin (45%
vs. 42%, respectively) [32].
In clinical practice, daptomycin is recommended at doses that are higher than approved (4–6
mg/kg) [6]. In small clinical studies, doses up to 12 mg/kg every 24 hours have been
tolerated with no serious adverse events or treatment discontinuations noted [25].
Daptomycin is not indicated for use in the pediatric population, but its use has been
evaluated in several studies [102]. A study of 16 children with a median age of 6.5 years
evaluated use of daptomycin (4 mg/kg every 24 hours) in subjects with persistent bacteremia
or failing conventional antimicrobial therapy [33]. Bacteremia resolved within 72 hours in 6
of 7 subjects with prior positive blood cultures. No adverse drug events were observed
during daptomycin treatment [33]. A second study of daptomycin in which subjects aged 2–
17 years old (n=22) were given 4 mg/kg every 24 hours found that only 1 subject had an
adverse drug event (infusion site reaction), and no subjects withdrew from the study [28].
None of the 22 child subjects treated had elevations in CK values during treatment [28].
There are limited published data regarding the safety and efficacy of daptomycin in infants.
In a study of 20 infants with a median age of 32 weeks gestation (range 23–40 weeks), a
single dose of daptomycin (6 mg/kg) was administered, and there was no observed elevation
in CK levels or adverse drug events [29]. In a small report (n=3) of daptomycin use (6
mg/kg every 12 hours) in severely ill infants, no adverse drug events or elevated CK values
were recorded [34]. Treatment with daptomycin resulted in negative blood cultures at a dose
of 6 mg/kg every 12 hours in 2 subjects after 4 days and at a dose of 15 mg/kg every 12
hours in the third subject after 5 days [34]. A separate report (n=2) evaluated daptomycin (6
mg/kg every 12 hours) in severely ill preterm infants; no adverse drug event was observed in
either subject [30].
Ongoing Pediatric Research for Daptomycin
Four phase 1 studies for daptomycin have been completed in the pediatric population: 1) in
infants; 2) in children aged 3–24 months; 3) in children aged 2–6 years; and 4) in children
aged 2–17 years. Currently, there are 3 daptomycin trials that are recruiting pediatric
patients: 1) for treatment of children with bacterial meningitis; 2) a phase 1 study in children
with renal disease; and 3) a phase 4 comparative study versus vancomycin or clindamycin
for treatment of children with S. aureus bacteremia [202].
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Quinupristin/dalfopristin is the first of the injectable semisynthetic streptogramin
antibacterial agents, comprising quinupristin and dalfopristin in a 30:70 ratio [103]. The
drug has a unique mechanism of action that inhibits bacterial protein synthesis by each
molecule binding to different sites on the 50s subunit of the ribosome. When combined, they
are synergistic as binding of dalfopristin induces a conformational change in the 50s subunit
that increases the binding affinity of quinupristin [35]. The combination of both drugs has
bactericidal activity against gram-positive pathogens [35]. Quinupristin/dalfopristin has been
found in vitro to have an MIC90 of 0.25–1 μg/mL, 0.25–1 μg/mL, and 2.0–8.0 μg/mL against
staphylococci, streptococci, and enterococci, respectively [103].
Pharmacokinetics of Quinupristin/Dalfopristin
Quinupristin/dalfopristin is administered as an IV infusion at a dosage of 7.5 mg/kg every 12
hours in adults [103]. For the treatment of vancomycin-resistant Enterococcus faecium
bacteremia, the drug is dosed 7.5 mg/kg every 8 hours [103]. Quinupristin has been found in
adults to have a Vd of 0.45 L/kg, while dalfopristin has a Vd of 0.24 L/kg. The CL of
quinupristin and dalfopristin are 0.72 L/kg/h [103]. In healthy adults, quinupristin/
dalfopristin has biphasic elimination following single or multiple doses. The drug is
primarily eliminated hepatically, with 75% and 78% of quinupristin and dalfopristin,
respectively, being excreted in bile and recovered in feces as unchanged drug and active
metabolites [36,37,103]. Fifteen percent of quinupristin and 19% of dalfopristin are excreted
through the urine as unchanged drug and active metabolites [36,37,103]. Quinupristin and
dalfopristin's T1/2 are 0.85–1.26 hours and 0.70–1.15 hours, respectively (Table 2) [38–41].
We were not able to identify any published PK studies of quinupristin/dalfopristin in
children and infants.
Safety and Efficacy of Quinupristin/Dalfopristin
Two phase 3 comparative trials of quinupristin/dalfopristin have been conducted for the
treatment of complicated skin and skin structure infection in adults (n=893) [42]. Subjects
were either given quinupristin/dalfopristin (7.5 mg/kg every 12 hours) or a comparator
medication (IV cefazolin 1 g every 8 hours, oxacillin 2 g every 6 hours, or vancomycin 1 g
every 12 hours). In these studies, quinupristin/dalfopristin-treated subjects experienced more
non-venous, drug-related adverse events than subjects treated with comparator medication
(21% vs. 13%, P<0.001) [42]. In subjects treated with quinupristin/dalfopristin, only nausea
was reported in >5% of subjects (6% vs. 2% for comparator, P=0.002). Adverse venous
events, most commonly injection site pain and inflammation, occurred more often in
subjects treated with quinupristin/dalfopristin than in those treated with comparator
medication (66% vs. 28%, P<0.001) [42]. Discontinuation due to an adverse event occurred
more often in the quinupristin/dalfopristin group than in the comparator group (19% vs.
5%). However, discontinuation due to treatment failure occurred more often in the
comparator group than in the quinupristin/dalfopristin group (11% vs. 5%). The clinical
success rate of quinupristin/dalfopristin for the treatment of skin and skin structure
infections was similar to treatment with comparator medications (68% vs. 71%,
respectively) [42].
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In non-comparator studies (n=972), major adverse events possibly related to quinupristin/
dalfopristin administration included severe arthralgia and myalgia, each of which occurred
in 3% of subjects [103]. A second study examining the efficacy and safety of quinupristin/
dalfopristin for the treatment of vancomycin-resistant E. faecium infection (n=396) reported
higher rates of arthralgia (9%) and myalgia (7%) [43].
Limited studies have evaluated the safety and efficacy of quinupristin/dalfopristin in
children. The drug is not labeled for use in infants or children [44]. A retrospective study
examined the safety and efficacy of quinupristin/dalfopristin dosed at 7.5 mg/kg every 8
hours in children (n=127) <18 years of age with a confirmed gram-positive bacterial
infection that was resistant to conventional treatment [44]. Multiple clinical syndromes were
treated, including bacteremia of unknown source, intra-abdominal infection, catheter-related
infection, skin and skin structure infection, urinary tract infection, bone and joint infection,
respiratory tract infection, and endocarditis. The mean age of subjects was 7.3 years (range
0.1–17.8). Pathogens included vancomycin-resistant E. faecium (80%), Enterococcus spp.
(7%), MRSA (6%), and S. epidermidis (4%). Successful clinical response to quinupristin/
dalfopristin treatment was demonstrated in 69% of subjects and was similar across all age
groups; the microbiological response rate was 78% [44]. The clinical response rates are
similar to the response rates that are seen in the adult population (68%) [42,45]. The drug
was well tolerated in this population, with only 3% of subjects receiving the drug through a
central venous catheter experiencing a venous adverse event. Eight percent of subjects
experienced non-venous adverse events, the most frequent being pain (2%) and
maculopapular rash (2%) [44]. Significant elevations in aspartate aminotransferase values
were observed in 44% of subjects, with 7% of subjects having levels >5 times the upper
limit of normal. Furthermore, 42% of subjects experienced elevated levels of bilirubin; 25%
of subjects had a bilirubin level >5 times the upper limit of normal during the course of
treatment [44].
A prospective, observational, safety and efficacy study of quinupristin/dalfopristin in infants
and children (n=19) being treated for glycopeptide-resistant E. faecium (GREF) infection
post liver transplant reported promising results [46]. Subjects had a median age of 1.5 years
(range 0.1–16) and were given quinupristin/dalfopristin (7.5 mg/kg) by slow infusion
through a central venous catheter every 8–12 hours. GREF infection was defined as clinical
criteria for infection accompanied by isolation of GREF from blood culture, intravascular
device tips, or repeated isolation from urine [46]. Complete resolution of GREF infection
was reported in 74% of subjects with resolution of fever/leukocytosis and negative cultures.
Sixteen percent of subjects had a partial response with negative cultures but recurrence of
fever upon treatment discontinuation. Ten percent of subjects had negative cultures but no
clinical improvement. Adverse events included elevated alkaline phosphatase in 4 subjects
that returned to normal following treatment completion. No arthralgia or myalgia was
reported, as subjects in this study were too young or too critically ill to report these adverse
reactions [46]. The authors concluded that the drug could be safely administered, with
minimal side effects, to critically ill pediatric subjects [46].
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Ongoing Pediatric Research for Quinupristin/Dalfopristin
There are currently no active, completed, or open trials for quinupristin/dalfopristin in the
pediatric population [202].
Telavancin
Telavancin is a lipoglycopeptide antibacterial agent that is a synthetic derivative of
vancomycin [47]. Telavancin has bacteriostatic activity against gram-positive organisms as
the drug inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors,
thereby inhibiting peptidoglycan polymerization and subsequent cross-linking [47,48].
Moreover, telavancin was also found to have bactericidal activity against gram-positive
organisms as the drug is also able to disrupt the bacterial cell membrane, causing cell
membrane potential depolarization [48,49]. Telavancin has been found in vitro to have
MIC90 values of 0.5 μg/mL, 0.03–0.06 μg/mL, and 16 μg/mL against MRSA, streptococci,
and vancomycin-resistant enterococci, respectively [50,51].
Pharmacokinetics of Telavancin
Telavancin is given as an IV infusion at a dose of 10 mg/kg every 24 hours in adults [104].
The PK of the drug following single and multiple dosing has been well studied in the adult
population [52–54]. Telavancin exhibits linear PK in adults over the dose range of 7.5–15
mg/kg every 24 hours [54]. The steady state Vd of telavancin is 0.1–0.15 L/kg, and it is 90–
93% bound to plasma proteins, primarily serum albumin [47,54,104]. T1/2 of the drug in
adults is approximately 6–8 hours [54,104]. The estimated CL of telavancin is 0.012–0.014
L/kg/h (Table 2) [54,104]. Telavancin is primarily excreted renally, with over two thirds of
the drug being excreted unchanged in the urine [54]. The PK of telavancin has not been
studied in children or infants.
Safety and Efficacy of Telavancin
The safety and efficacy of telavancin in adults have been evaluated in 3 large clinical studies
[55]. The drug has not been evaluated in the pediatric population. One study in adults
(n=195) with complicated skin and skin structure infections compared telavancin 10 mg/kg
every 24 hours against vancomycin 1 g every 12 hours or nafcillin/oxacillin 2 g every 6
hours [55]. A similar percentage of subjects given telavancin or a comparator medication
experienced at least 1 adverse event (56% vs. 57%, P≥0.99). In patients taking telavancin,
adverse events that occurred in >5% of subjects and at a higher rate than in the comparator
group included: nausea (16% vs. 6%, P=0.04), taste disturbance (14% vs. 0%, P<0.01), and
insomnia (13% vs. 3%, P=0.02). Serious adverse events occurred more often in subjects
treated with telavancin than in the comparator group (7 subjects vs. 3 subjects). The
discontinuation rate for telavancin due to adverse events was higher but not statistically
different from the comparator treatment (6% vs. 3%). Clinically evaluable cure rates for
telavancin were similar to comparator medication for the treatment of complicated skin and
skin structure infection (96% vs. 94%, P=0.53) [55].
A second study in adults (n=1867) with complicated skin and skin structure infection
compared telavancin versus vancomycin therapy [56,57]. Subjects were either given
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telavancin at a dose of 10 mg/kg every 24 hours or vancomycin 1 g every 12 hours. At least
1 adverse event occurred more often in telavancin-treated subjects than in subjects treated
with vancomycin (79% vs. 72%) [56,57]. Serious adverse events occurred more frequently
in the telavancin-treated group than in the vancomycin-treated group (7% vs. 4%).
Discontinuation rates were also higher in the telavancin-treated group (8% vs. 6%) [56,57].
Adverse events among subjects taking telavancin that occurred in >5% of subjects and at a
higher rate than in the comparator group included taste disturbance (33% vs. 7%), nausea
(27% vs. 15%), and vomiting (14% vs. 7%) [56,57]. The clinical cure rate among subjects
with MRSA isolated at baseline was higher in subjects treated with telavancin than in
subjects treated with vancomycin (89% vs. 85%) [56].
A third comparator study in adults (n=1503) examined the safety and efficacy of telavancin
versus vancomycin for the treatment of hospital-acquired pneumonia caused by gram-
positive organisms [58]. Adverse events occurred equally in both telavancin-treated subjects
and vancomycin-treated subjects (82% vs. 82%). Telavancin-treated subjects experienced
more serious adverse events than vancomycin-treated subjects (31% vs. 26%). Treatment
discontinuation was higher among telavancin-treated subjects (8% vs. 5%). Cure rates
among telavancin-treated subjects were non-inferior to cure rates among vancomycin-treated
subjects for pneumonia caused by all S. aureus (78% vs. 75%) and for pneumonia caused by
MRSA (75% vs. 75%) [58].
Ongoing Pediatric Research for Telavancin
Telavancin is being studied in the pediatric population. There is 1 planned study examining
the single-dose PK of the drug given at 10 mg/kg in pediatric subjects aged 1–17 years
[202].
Ceftaroline
Ceftaroline is a recently approved broad-spectrum cephalosporin indicated for the treatment
of MRSA infection [59]. Ceftaroline has bactericidal activity against gram-positive
organisms as the drug binds penicillin-binding protein, preventing synthesis of the bacterial
cell wall [59]. MRSA strains developed antibiotic resistance through the acquisition of
PBP-2a, to which many cephalosporins and beta-lactams have low affinity. However,
ceftaroline has been found to have a high affinity to PBP-2a and is effective in the treatment
of MRSA infection [59]. The drug is highly effective against gram-positive bacteria and has
been found in vitro to have MIC90 values of 0.5–2 μg/mL, 0.01–0.5 μg/mL, and 8 μg/mL
against MRSA, streptococci, and vancomycin-resistant enterococci, respectively [60,61].
Pharmacokinetics of Ceftaroline
Ceftaroline is given as an IV infusion at a dosage of 600 mg every 12 hours in adults [105].
The PK of ceftaroline following single and multiple dosing has been studied in the adult
population. Ceftaroline follows linear PK within a dosing range of 50–1000 mg [105]. The
steady state Vd of ceftaroline following a single 600 mg dose of the drug was 20 L (range
18– 21), and the drug is 20% bound to plasma proteins [105]. The T1/2 of the drug is
approximately 2.5 hours [62,105]. The CL of the drug in adults is 8.7–9.6 L/h [62,105].
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Ceftaroline and its metabolites are primarily excreted renally, with approximately 88% of
the drug being recovered in the urine following a single 600 mg IV dose of radiolabeled
drug [105]. The PK of ceftaroline has not been reported in children or infants.
Safety and Efficacy of Ceftaroline
The safety and efficacy of ceftaroline have been evaluated in a number of large clinical
studies in adults. A study in adults (n=100) compared ceftaroline versus standard therapy for
the treatment of complicated skin and skin structure infection [63]. Subjects were given
either ceftaroline 600 mg every 12 hours or vancomycin 1 g every 12 hours. Only subjects
given standard treatment could be switched from vancomycin to a penicillinase-resistant
penicillin if baseline cultures indicated that the pathogen was susceptible. Adverse events
occurred at similar rates in the ceftaroline-treated group and the standard therapy group
(61% vs. 56%). The only adverse event to occur more commonly among ceftaroline-treated
subjects was nausea (6% vs. 0%) [63]. Three serious adverse events occurred in ceftaroline-
treated subjects, none of which were treatment-related [63]. Subjects given ceftaroline
experienced fewer generalized infusion reactions than standard therapy (0% vs. 9%) [63].
Clinical cure rates at end of treatment were similar between ceftaroline and standard therapy
(98% vs. 96%, respectively) [63].
Two large studies, CANVAS 1 (n=702) and CANVAS 2 (n=694), evaluated ceftaroline
versus vancomycin plus aztreonam for the treatment of complicated skin and skin structure
infection [64–66]. Subjects were either given ceftaroline at 600 mg every 12 hours or
vancomycin at 1 g every 12 hours plus aztreonam 1 g every 12 hours. Integrated analysis of
both trials showed that adverse events occurred at similar rates in both the ceftaroline- and
vancomycin-treated groups. Drug-related adverse events in >3% of subjects that occurred
more often in ceftaroline-treated subjects included nausea (6% vs. 5%) and diarrhea (5% vs.
4%). Pruritus occurred more often in subjects treated with vancomycin than in those treated
with ceftaroline (8% vs. 4%) [66]. More subjects discontinued vancomycin plus aztreonam
treatment than did those treated with ceftaroline (5% vs. 3%) [66]. Clinical efficacy as
measured by cure rate in microbiologically evaluable subjects showed that ceftaroline was
non-inferior to standard treatment (93% vs. 94%). However, clinical cure rates for
ceftaroline-treated subjects were lower than standard therapy when the pathogen isolated
was a gram-negative organism (85% vs. 100%) [66].
FOCUS 1 (n=613) and FOCUS 2 (n=627) were 2 large clinical trials that compared
ceftaroline versus standard therapy with ceftriaxone for the treatment of community-
acquired pneumonia [67,68]. Subjects were either given IV ceftaroline at 600 mg every 12
hours or IV ceftriaxone at 1g every 24 hours.
In the FOCUS 1 study, adverse events occurred at similar rates in ceftaroline-treated
subjects and ceftriaxone-treated subjects (40% vs. 44%, respectively). No adverse event
occurred in >5% of treated subjects. Common adverse events that occurred at >3% rate and
more often in ceftaroline-treated subjects included diarrhea (5% vs. 2%), insomnia (3% vs.
2%), and headache (3% vs. 1%). Drug-related severe adverse events occurred less frequently
in ceftaroline-treated subjects (2 subjects vs. 8 subjects). The 2 severe adverse events in
ceftaroline-treated subjects included 1 case of sudden death and 1 abnormal liver function
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test. At end of therapy, ceftaroline was found to have a higher cure rate for community-
acquired pneumonia than ceftriaxone (88% vs. 80%) [67].
In the FOCUS 2 study, adverse events occurred at similar rates in ceftaroline-treated
subjects and ceftriaxone-treated subjects (20% vs. 17%)—rates that were lower than those
seen in FOCUS 1. Common adverse events that occurred at >3% rate and more often in
ceftaroline-treated subjects included diarrhea (4% vs. 3%), headache (4% vs. 2%), and
hypokalemia (3% vs. 2%). One drug-related severe adverse event, convulsion, occurred
among ceftaroline-treated subjects. At end of therapy, ceftaroline showed non-inferiority to
ceftriaxone for the treatment of community-acquired pneumonia (86% vs. 80%) [68].
Ongoing Pediatric Research for Ceftaroline
Ceftaroline is being studied in the pediatric population. One phase 1 study examining the PK
of the drug in subjects aged 12–17 years has been conducted, the results of which have not
been published. Also, 2 studies are recruiting patients: 1) a phase 3 comparator study of
ceftaroline versus vancomycin for the treatment of skin and skin structure infection in
pediatric patients; and 2) a phase 3 comparator study of ceftaroline versus ceftriaxone for the
treatment of pediatric patients with community-acquired bacterial pneumonia [202].
Tigecycline
Tigecycline is a broad-spectrum glycylcycline antibiotic indicated for the treatment of
MRSA infection [69,106]. The drug reversibly binds to the 30S ribosomal subunit,
inhibiting the synthesis of bacterial proteins [69]. Tigecycline is generally thought to be
bacteriostatic, but the drug does have bactericidal activity against gram-positive organisms
at concentrations 4 times greater than the MIC90 concentration [70,106]. Tigecycline has
been found in vitro to have MIC90 values of 0.25–1 μg/mL, 0.25 μg/mL, and 0.25 μg/mL
against MRSA, streptococci, and enterococci, respectively [71,106].
Pharmacokinetics of Tigecycline
In adults, tigecycline is given as an IV infusion [106]. In adults, a 100 mg loading dose is
initially administered, followed by a maintenance dose of 50 mg every 12 hours. The PK of
tigecycline in adults has been studied following single and multiple dosing. Tigecycline
follows linear PK for single doses of 12.5 mg to 300 mg and for multiple doses of 25–100
mg every 12 hours [72]. The steady state Vd of tigecycline following 50–100 mg dosing
every 12 hours is 7.2–9.1 L/kg. Tigecycline is 73–91% bound to serum proteins at serum
concentrations from 0.1–1 μg/mL [72,106]. The T1/2 of the drug following a single 100 mg
infusion has been found to be between 16.5 and 27.1 hours [73,106]. The CL of tigecycline
is 0.2–0.3 L/kg/h (Table 2) [72]. The primary route of excretion of tigecycline and its
metabolites is through biliary excretion (59%) and renal excretion (33%) [106].
The PK of tigecycline in children has been studied in 2 separate studies. Both studies aimed
to determine tigecycline dosing such that the AUC measurements in children approximated
AUC0-24 levels in adults, as prior studies had shown the AUC0-24/MIC ratio to be a good
predictor of clinical response [74]. The first study examined the PK of tigecycline following
an ascending dose in children aged 8–16 years. Based on the AUC0-24 parameter, the study
Gostelow et al. Page 12






















authors concluded that a dose of 1 mg/kg every 12 hours in children above age 12 years
most closely approximated adult AUC0-24 levels known to be therapeutically effective
[75,106]. A subsequent phase 2 study (n=58) examined the PK of tigecycline in children
aged 8–11 years [75]. Tigecycline was given to subjects enrolled in 3 different cohorts at
dosages of 0.75 mg/kg every 12 hours, 1 mg/kg every 12 hours, or 1.25 mg/kg every 12
hours (Table 2). The estimated AUC0-24 values that most closely approximated adult values
were observed in children receiving approximately 1.2 mg/kg tigecycline every 12 hours
[75].
Safety and Efficacy of Tigecycline
The safety and efficacy of tigecycline have been evaluated in a number of large clinical
studies in adults. One phase 3 study in adults (n=157) compared tigecycline versus standard
therapy for the treatment of complicated skin and skin structure infection [76]. Subjects
were given either tigecycline 100 mg loading dose followed by 50 mg every 12 hours or
vancomycin 1 g every 12 hours. Adverse events occurred at similar rates in tigecycline-
treated subjects and vancomycin-treated subjects (69% vs. 67%, respectively).
Gastrointestinal adverse events occurred more frequently in tigecycline-treated subjects than
in vancomycin-treated subjects, which included nausea (29% vs. 8%) and vomiting (19% vs.
3%). Serious adverse events occurred at similar rates in tigecycline- and vancomycin-treated
subjects (20% vs. 21%, respectively), as did treatment discontinuation (7% vs. 5%,
respectively) [76].
A second phase 3 study in adults (n=1116) also compared tigecycline versus vancomycin for
the treatment of complicated skin and skin structure infection [77]. Subjects were given
either tigecycline 100 mg loading dose followed by 50 mg every 12 hours or vancomycin 1
g every 12 hours. Treatment-emergent adverse events occurred more frequently in
tigecycline-treated subjects than in vancomycin-treated subjects (68% vs. 61%, P=0.02) but
were either mild in nature or deemed by investigators to not be due to study medication [77].
Gastrointestinal adverse events occurred more frequently in tigecycline-treated subjects than
in vancomycin-treated subjects, which included nausea (35% vs. 8%) and vomiting (20% vs.
4%). Treatment discontinuation occurred at similar rates in tigecycline- and vancomycin-
treated subjects (4% vs. 5%, P=0.2) [77].
There are few studies examining the safety and efficacy of tigecycline in the pediatric
population. In 2010, the FDA warned that treatment with tigecycline was associated with an
increased risk of death despite the drug having demonstrated non-inferiority to comparator
medication for the treatment of skin and skin structure infection, community-acquired
pneumonia, and intra-abdominal infection [78,106]. Pooled analysis of 13 randomized
controlled trials found that tigecycline was associated with a 0.7% absolute increase in
mortality or a 30% relative increase in mortality versus comparator drugs. Furthermore,
pooled analysis showed that tigecycline was found to have a higher absolute non-cure rate of
2.9% versus comparator medication [78]. Possible reasons for this finding of increased
mortality and lower absolute cure rate for tigecycline treatment versus comparator treatment
include inadequate antimicrobial activity of the drug, inadequate dosing, and possible drug
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toxicity [78]. Due to the finding of increased mortality in adults, further trials evaluating the
safety and efficacy of tigecycline in the pediatric population have not been conducted [106].
Prior to the FDA warning, safety and efficacy data for the pediatric population was reported
in one phase 2 study of tigecycline (n=58) previously described [79]. Children 8–11 years of
age were given tigecycline at 0.75–1.25 mg/kg every 12 hours. Adverse events were
reported by 79% of subjects: 50% of subjects experienced nausea. Five percent of subjects
experienced serious adverse events including postoperative wound infection (2%), anal
fistula (2%), and abdominal pain (2%). All serious adverse events resolved by the end of the
study. Treatment discontinuation occurred in 4% of subjects [79].
Future Pediatric Research for Tigecycline
Tigecycline has had 1 completed phase 1 study that examined the PK of the drug in pediatric
subjects aged 8–11 years. There are currently no other active or open trials for this drug in
the pediatric population [202].
Expert Commentary
Antibiotic resistance continues to be a major healthcare concern. In the United States, from
1999 to 2008, the proportion of staphylococcal infections resistant to methicillin and the
incidence of MRSA infection have increased substantially. Over the last 15 years, 6 drugs
have been approved for the treatment of S. aureus infections. PK and safety data in infants
are only available for linezolid and daptomycin.
To combat the increase in infections caused by antibiotic-resistant organisms, more drug
research in infants is needed for recently approved medications. While it is encouraging that
clinical trials in children are underway for non-labeled drugs such as ceftaroline,
daptomycin, and telavancin, it should be noted that none of these clinical trials is enrolling
infants.
Infants, especially premature infants, have a unique and developing physiology. Rigorous
studies are needed to evaluate PK/pharmacodynamic (PD) properties in this population.
Linear extrapolation of adult dosing to infants is not advisable as drug elimination pathways
are not linearly related to body weight. There are many unique challenges to studying drugs
in infants, leading to a paucity of pharmacology trials in this population. These challenges
include low parental consent rates and limited blood volumes for PK analysis [80].
Opportunistic studies address some of these challenges. Many off-label drugs are already
given to infants as part of standard medical care. As the drug is already being administered
to the infant, parental consent is needed only for specimen collection. Investigators can
avoid additional blood draws by conducting scavenged sampling of residual specimen from
the lab following the completion of ordered tests, or sparse sampling of only 2–3 low-
volume specimens that can be collected with routine laboratory draws. The development of
micro-analytical techniques has increased the accuracy of PK data obtained from sparse
sampling and scavenged sampling. Low-volume plasma drug assays and dried blood spot
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sampling allow for the accurate measurement of drug concentrations from <100 μL and <30
μL of specimen, respectively.
Sparse and scavenged sampling data can be modeled using population PK/PD analyses to
generate population estimates and account for sources of between-subject variability.
Population estimates can then be used to obtain individual estimates for each subject.
Opportunistic studies using sparse and scavenged sampling have already been conducted to
describe the population PK of several drugs in premature infants including fluconazole,
cefepime, and amoxicillin [81–83].
Current legislation in the form of the Best Pharmaceuticals for Children Act (BPCA) aims to
increase clinical research in the pediatric population. The BPCA allows the FDA to issue
specific written requests to drug sponsors requesting clinical trials in the pediatric
population be performed, with the incentive of granting an additional 6 months of patent
exclusivity to the drug sponsor should the trials be conducted. Moreover, under the Food
and Drug Administration Innovation and Safety Act (FDASIA), the FDA must provide a
specific rationale if written requests for future studies do not include neonates.
In the event that the drug sponsors choose to not fulfill the written request, the BPCA further
gives the National Institutes of Health (NIH) the responsibility of creating a priority list of
drugs needing further study in the pediatric population. The National Institute of Child
Health and Human Development (NICHD) is responsible for the research of prioritized
drugs, with the goal of improving pediatric therapeutics through clinical trials that lead to
drug label changes.
Vancomycin is frequently the drug of choice for the treatment of serious MRSA infection in
infants. Linezolid is approved by the FDA for use in premature and term infants. Linezolid
has been studied in infants, and a dose of 10 mg/kg every 24 hours approximates adult
dosing of 600 mg/day. The safety of linezolid in infants has been shown to be similar or
better than vancomycin. Infants administered linezolid should have complete blood counts
measured weekly due to associated myelosuppression. Although daptomycin is not FDA-
approved for use in infants, the PK of daptomycin has been studied in infants, suggesting
that the weight-normalized clearance of the drug in infants is higher than in adults. Due to
the increased body weight-normalized CL of the drug in infants, doses of 6 mg/kg every 12
hours have shown a similar drug exposure to adult doses of 4 mg/kg every 24 hours.
Although limited, data suggest daptomycin is well tolerated. Infants receiving daptomycin
should have CK levels monitored.
Quinupristin/dalfopristin has been studied in non-infant pediatric populations. There are no
PK, safety, or efficacy studies of the drug in infants. There are also no clinical trials actively
enrolling patients to study quinupristin/dalfopristin use. Lastly, as quinupristin/dalfopristin is
not indicated for the treatment of MRSA infection, we believe that there are better drug
choices for the treatment of MRSA infection in infants. Ceftaroline and telavancin have
been shown to be effective drugs for the treatment of MRSA infection in adults. However,
neither drug has been studied in infants.
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Future treatment of MRSA infection in infants will come from drugs that are currently in
phase 3 clinical trials. Newly developed antibiotics against gram-positive bacteria for the
treatment of skin and skin structure infection include tedizolid, dalbavancin, oritavancin, and
omadacycline [203]. One phase 1 PK study in adolescents has been completed for both
tedizolid and dalbavancin [202]. There are currently no other active, open, or completed
studies for either drug according to publicly available databases. No clinical trials in the
pediatric population have been completed or are underway for oritavancin or omadacycline.
Moreover, no infant studies for these 4 drugs are underway or have been completed
according to ClinicalTrials.gov.
The 2003 Pediatric Research and Equity Act (PREA) mandated that a pediatric study plan
be created for all new drug applications should the drug have a new active ingredient,
indication, dosage form, dosing regimen, or route of administration [107]. The pediatric
study plan should be created by the end of phase 2 of development and should include plans
to study drug dosing, safety, and effectiveness in children. Extrapolation from adult data
may be used to determine pediatric drug effectiveness. PREA mandates pediatric studies for
all antibiotics that are in development, including tedizolid, dalbavancin, oritavancin, and
omadacycline.
Investigators in collaborative research networks (e.g., Pediatric Trials Network,
www.pediatrictrials.org) can continue to incorporate opportunistic studies into clinical
research, as these studies are low-risk and have a high-yield potential.
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• The proportion of staphylococcal isolates that are MRSA has increased, and the
incidence of MRSA infection has increased 10-fold.
• Antibacterial agents that have been approved in adults over the past 15 years for
the treatment of skin and skin structure infection caused by staphylococcal
bacteria include linezolid, daptomycin, quinupristin/dalfopristin, ceftaroline,
telavancin, and tigecycline.
• Of the 6 recently approved antibiotics, linezolid is the only antibiotic to be
labeled for use in infants and premature infants.
• Clinical studies for ceftaroline, telavancin, and daptomycin are underway for
pediatric patients. However, none of these studies is examining the drug in the
infant population.
• Extrapolation of efficacy data from well-controlled adult trials is a possible
method to accelerate drug labeling in infants and other pediatric populations.
• Antibiotics in phase 3 of development include tedizolid, dalbavancin,
oritavancin and omadacycline. Few clinical trials have been completed for these
medications in the pediatric population. No trials in infants are underway or
have been completed for any of these drugs.
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